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The increasing prevalence of multidrug-resistant bacteria urges the development of
new antibacterial agents. With a broad spectrum activity, antimicrobial peptides have
been considered potential antibacterial drug leads. Using bioinformatic tools we have
previously shown that viral structural proteins are a rich source for new bioactive
peptide sequences, namely antimicrobial and cell-penetrating peptides. Here, we
test the efficacy and mechanism of action of the most promising peptides among
those previously identified against both Gram-positive and Gram-negative bacteria.
Two cell-penetrating peptides, vCPP 0769 and vCPP 2319, have high antibacterial
activity against Staphylococcus aureus, MRSA, Escherichia coli, and Pseudomonas
aeruginosa, being thus multifunctional. The antibacterial mechanism of action of the
two most active viral protein-derived peptides, vAMP 059 and vCPP 2319, was studied
in detail. Both peptides act on both Gram-positive S. aureus and Gram-negative
P. aeruginosa, with bacterial cell death occurring within minutes. Also, these peptides
cause bacterial membrane permeabilization and damage of the bacterial envelope of
P. aeruginosa cells. Overall, the results show that structural viral proteins are an abundant
source for membrane-active peptides sequences with strong antibacterial properties.
Keywords: antimicrobial peptides (AMPs), cell-penetrating peptides (CPPs), minimum inhibitory concentration
(MIC), minimal bactericidal concentration (MBC), membrane permeabilization, atomic force microscopy (AFM)
INTRODUCTION
Bacterial resistance to conventional antibiotics has increased drastically during the last decades,
making difficult the effective treatment of infections caused by drug-resistant bacteria (Tanwar
et al., 2014; Brown, 2015). According to a recent report from the World Health Organization
(WHO, 2014), it is estimated that each year, in the European Union alone, over two million
people become infected with resistant bacteria, of which 25,000 die. Also, it has been described that
methicillin-resistant Staphylococcus aureus kills more Americans each year than HIV, Parkinson’s
disease, emphysema, and homicide combined (Ventola, 2015). This represents a real threat to
human health worldwide and has driven the search for novel effective antibacterial agents.
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Antimicrobial peptides (AMPs) have emerged as potential
alternatives to currently used antibiotics (Zasloff, 2002; Baltzer
and Brown, 2011). This group of molecules can be found in
all life forms, from microorganisms to plants and animals, and
are known to have broad spectrum activity against multiple
microorganisms, including bacteria, fungi, viruses and parasites
(Zasloff, 2002; Jenssen et al., 2006; Nguyen et al., 2011). AMPs
are very diverse in their amino acid sequences and folding
(Hancock, 2001; Powers and Hancock, 2003; Peters et al.,
2010), and display mechanisms of action that are distinct from
the ones used by conventional antibiotics (Sancho-Vaello and
Zeth, 2015). It has been proposed that the first step in their
action involves the contact with bacterial membranes, which
occurs through electrostatic and hydrophobic interactions with
negatively charged lipids on the cell membrane (Yeaman and
Yount, 2003; Teixeira et al., 2012). Membrane-targeting is
usually followed by permeabilization and disruption of the lipid
bilayer structure, leading to loss of integrity and ultimately
cell death (Shai, 2002). Alternatively, some AMPs can exert
their antimicrobial activity by targeting intracellular metabolic
processes without damaging membrane integrity (Park et al.,
2000; Brogden, 2005; Bahar and Ren, 2013). Currently, some
AMPs are already clinically available, such as the cationic
lipopeptide polymyxin B (Sandri et al., 2013) and the cyclic
cationic peptide gramicidin S (Mogi and Kita, 2009), and many
are in clinical development (Mahlapuu et al., 2016).
Peptide sequences with antimicrobial properties have been
identified using different approaches, such as, identification
of bioactive compounds on natural extracts (Bulet et al.,
2004), in silico analysis of natural proteins (Torrent et al.,
2012), de novo or structure-based design, or chimeras of
peptide fragments (Piers et al., 1994; Wu and Hancock,
1999; Rozek et al., 2003; Brogden and Brogden, 2011). Since
enveloped viruses are abundant in multifunctional proteins,
using bioinformatic tools we searched structural viral proteins
for bioactive peptides sequences (Freire et al., 2015a), namely
AMPs and cell-penetrating peptides (CPPs). CPPs are a group
of peptides capable of crossing biological membranes without
causing significant membrane damage (Gräslund et al., 2011).
Given the similarities in the structure and activity between these
two groups of peptides, it has been proposed that CPPs are not
totally distinct from AMPs (Henriques et al., 2006; Zhu et al.,
2006; Splith and Neundorf, 2011).
In this study, we intended to investigate the antibacterial
activity and mechanism of action of previously identified viral
protein-derived peptides (Table 1) (Freire et al., 2015a). First, the
potential antibacterial activity of six selected viral protein-derived
peptides proven to have cell-penetrating properties (vCPPs) was
evaluated against Gram-positive and Gram-negative bacteria.
The results obtained allowed to identify two vCPPs with high
antibacterial activity, vCPP 0769 and vCPP 2319, showing that
viral protein-derived sequences are a possible source for peptides
with dual action. Furthermore, the antibacterial mechanism of
action of the two most active viral protein-derived peptide
sequences, vAMP 059, previously identified (Freire et al., 2015a),
and vCPP 2319, was investigated and the results show that the
peptides act mainly through a mechanism involving membrane
disruption. This study shows the potential of viral structural
proteins as a source of bioactive peptides sequences with
antibacterial properties.
MATERIALS AND METHODS
Peptide Selection and Synthesis
Peptide selection was performed based on a previous study
(Freire et al., 2015a) in which viral proteins were searched for
AMPs and CPPs using AMPA and CellPPD bioinformatic tools,
respectively. The AMPA server (Torrent et al., 2012) is based
on an antimicrobial propensity scale that considers the physical
chemical properties of each amino acid, such as hydrophobicity
and amphipathicity, and the relevance of amino acid position
for antimicrobial activity. An antimicrobial index (AI) < 0.225
was considered a positive hit for an AMP. CellPPD is a Support
Vector Machine (SVM) that scores each amino acid residue
sequence with a SVM score (Gautam et al., 2013). A SVM > 0
was considered a positive CPP hit. Several peptide sequences were
selected for experimental validation, based on their sequence
novelty (when compared to the AMP/CPP sequences listed on
the existing databases) and best ranking in AI and SVM score.
The selection covered a broad range of scores and peptide
sequence physical–chemical properties such as hydrophobicity
and amphipathicity. The most active peptides were selected for
the present study.
All the peptides have an amidated C-terminus and a free
amine N-terminus. The viral protein-derived CPPs (vCPPs)
used in this study, Table 1, were synthesized by Bachem AG
(Bubendorf, Switzerland) with a purity of >95%. The viral
protein-derived AMP used, vAMP 059 (Table 1), was synthesized
on a standard Fmoc-Rink amide MBHA resin, using a Liberty 1
Microwave Peptide Synthesizer (CEM Corporation, Mathews,
NC, USA). Standard Fmoc/tBu SPPS protocols were applied
following procedures previously reported by us (Monteiro
et al., 2015; Barbosa et al., 2017). The crude peptide was
purified by preparative HPLC to a final 100% purity, as
evaluated by analytical HPLC. The pure peptide was analyzed
by electrospray-ionization/ion-trap mass spectrometry (ESI-IT
MS). The average calculated mass and observed mass values of
all vCPPs and vAMP 059 are shown in Supplementary Table S1.
To prepare stock solutions lyophilized peptides were weighed
out on a high precision analytical microbalance (0.01 mg± 0.02),
dissolved in sterile Milli-Q water and stored at –20◦C.
Antibacterial Activity Assay
The antibacterial activity of the vCPPs was tested using
a standard broth microdilution procedure (Wikler et al.,
2006; Wiegand et al., 2008) to evaluate the bacterial growth
inhibition and determine the minimal inhibitory concentration
(MIC). The assay was performed using the following strains:
Gram-positive Staphylococcus aureus (S. aureus) ATCC 25923
and methicillin-resistant Staphylococcus aureus (MRSA) ATCC
33591, and Gram-negative Escherichia coli (E. coli) ATCC 25922
and Pseudomonas aeruginosa (P. aeruginosa) ATCC 27853,
obtained from American Type Culture Collection (ATCC)
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TABLE 1 | Viral protein-derived peptides used in this study.
Name Sequence Length Net charge Source (protein:position)
vCPP 0275 KKRYKKKYKAYKPYKKKKKF-NH2 20 +14 Cauliflower mosaic virus (Capsid: aa367–387)
vCPP 0417 SPRRRTPSPRRRRSQSPRRR-NH2 20 +11 Hepatitis B virus genotype C (Capsid: aa155–175)
vCPP 0667 RPRRRATTRRRITTGTRRRR-NH2 20 +12 Human Adenovirus C serotype 1 (Minor Core Protein – Capsid: aa314–334)
vCPP 0769 RRLTLRQLLGLGSRRRRRSR-NH2 20 +10 Fowl adenovirus A serotype 1 (Major Capsid Protein: aa17–37)
vCPP 1779 GRRGPRRANQNGTRRRRRRT-NH2 20 +11 Barley Virus (Capsid: aa5–25)
vCPP 2319 WRRRYRRWRRRRRWRRRPRR-NH2 20 +16 Torque teno douroucouli vírus (Capsid: aa16–36)
vAMP 059 INWKKWWQVFYTVV-NH2 14 +3 Rotavirus VP7 (Capsid: aa94–107)
(Manassas, VA, USA). Bacterial suspensions were prepared
by direct suspension of morphologically similar colonies on
Mueller Hinton Broth (MHB) from BD (Franklin Lakes, NJ,
USA) to a final concentration of 1 × 106 CFU/mL, and
added to a sterile 96-well microtiter polypropylene plate from
Corning (Corning, NY, USA) containing two-fold dilutions
of each peptide. Final bacterial concentration was 5 × 105
CFU/mL whereas peptide concentrations ranged between 100
and 0.78 µM. The 96-well plate was incubated at 37◦C for
18 h. The MIC was defined as the lowest peptide concentration
required to inhibited visible bacterial growth. The assay was
performed in triplicate.
Bactericidal Activity Assay
To study the bactericidal activity of the most active viral
protein-derived peptides, the minimal bactericidal concentration
(MBC) was determined by a colony count assay (Barry
et al., 1999). After the MIC assay, aliquots were removed
from the wells with no visible bacterial growth, serially
diluted in MHB, plated on nutrient-rich trypcase soy agar
(TSA) plates from bioMérieux (Marcy l’Etoile, France), and
incubated at 37◦C for 24 h. After incubation, bacterial
colonies were counted and the MBC was defined as the
lowest peptide concentration that caused ≥99.9% cell death
of the initial bacterial inoculum. The assay was performed in
triplicate.
Time-Kill Assay
For viral protein-derived peptides displaying bactericidal activity,
bacterial killing kinetics was determined by a conventional
method based on colony counts obtained after different times
of exposure of the bacterial cells to the peptides (Barry et al.,
1999). The assay was performed using S. aureus and P. aeruginosa
as representative strains of Gram-positive and Gram-negative
bacteria, respectively. Bacterial suspensions prepared in MHB
at 5 × 105 CFU/mL were treated with each peptide at final
concentrations corresponding to their MBC, and incubated at
37◦C and 200 rpm. A control of bacterial suspensions without
peptide was performed under the same conditions. Aliquots
of untreated and peptide-treated bacterial suspensions were
withdrawn at 0, 15, 30, 60, 120, and 180 min, serially diluted in
MHB, and plated on TSA plates. Bacterial colonies were counted
after 24 h of incubation at 37◦C. Viable bacteria (in CFU/mL) are
reported as percentage of the control. The assay was performed
in triplicate.
SYTOX Green Uptake Assay
SYTOX R© Green (Invitrogen, Carlsbad, CA, USA) is a
high-affinity nucleic acid stain that only penetrates cells
with compromised plasma membranes and emits fluorescence
when bound to DNA (Roth et al., 1997). A SYTOX Green uptake
assay (Torcato et al., 2013; Sani et al., 2015) was performed
using P. aeruginosa to study the effect of viral protein-derived
peptides on those bacterial membranes. Bacterial suspensions
at 1 × 108 CFU/mL in MHB were centrifuged for 10 min at
4000× g and the pellet resuspended in 10 mM HEPES buffer, pH
7.4, containing 150 mM NaCl, to a final concentration of 5× 105
CFU/mL. The bacterial suspensions were incubated for 1 h at
37◦C and 200 rpm, with twofold dilutions of each bactericidal
viral protein-derived peptide in a range of concentrations starting
at their corresponding MBC. Peptide-treated bacterial cells were
incubated with 0.1 µM of SYTOX Green for 10 min, on ice
and protected from light. The fluorescence emission intensity
signal was measured by flow cytometry (excitation with 488 nm
laser and detection at 530 nm with 30 nm bandpass) and a total
of 50 000 events were recorded. Flow cytometry experiments
were performed using a BD LSR Fortessa from BD Biosciences
(San Jose, CA, USA). The percentage of permeabilized cells was
determined considering that untreated bacterial cells (negative
control) are 0% permeabilized and bacterial cells treated with
isopropyl alcohol (positive control) are 100% permeabilized. To
study the correlation between bacterial cell permeabilization
and viability, a viability assay using a colony count method
was used. Using the same conditions described for the SYTOX
Green uptake assay, untreated and peptide-treated bacterial
suspensions were incubated, aliquots were serially diluted in
HEPES buffer, and plated on TSA plates. Plates were incubated at
37◦C for 24 h. From the number of bacterial colonies obtained,
viable bacteria (in CFU/mL) are reported as percentage of the
control. The assays were performed in triplicate.
Atomic Force Microscopy (AFM) Imaging
Atomic force microscopy (AFM) imaging was used to study
the effect of the bactericidal viral protein-derived peptides on
P. aeruginosa cells. Bacterial suspensions at 1 × 108 CFU/mL
in MHB were centrifuged for 10 min at 4000 × g, and the
pellet resuspended in HEPES buffer to a final concentration of
1 × 107 CFU/mL. The bacterial suspensions were treated with
each peptide at concentrations corresponding to their MBC,
as well as the concentrations above and below their MBC,
and incubated for 1 h at 37◦C and 200 rpm. As control,
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untreated bacterial suspension was also incubated using the
same conditions. A 200 µL droplet of each test sample was
applied on a poly-L-lysine-coated glass slide and allowed to
deposit for 20 min at room temperature. Each sample was then
rinsed 10 times with sterile Milli-Q water and allowed to dry
for 30 min at room temperature. AFM images were acquired
using a JPK NanoWizard II (Berlin, Germany) mounted on a
Zeiss Axiovert 200 inverted microscope (Göttingen, Germany).
Measurements were carried out in air and in intermittent
contact mode using uncoated silicon ACL cantilevers from
APPNano (Mountain View, CA, USA). ACL cantilevers had
typical resonance frequencies of 190 kHz and a spring constant
of 45 N/m. Bacteria were first visualized through the optical
microscope before being selected for imaging. On average,
14 untreated bacteria and 10 individual bacterial cells were
imaged for each peptide concentration, with a total area of
4 µm × 4 µm from three independent bacterial preparation
slides. Height images were recorded and treated with JPK SPM
data processing 5.1.8.
RESULTS
Antibacterial Activity of vCPPs
The antibacterial activity of six viral protein-derived CPPs
(vCPPs; Table 1) was evaluated by determining the MIC
against S. aureus and MRSA, and E. coli and P. aeruginosa,
as representative models of Gram-positive and Gram-negative
bacteria, respectively. The MIC values obtained for each peptide
are presented in Table 2. Among the vCPPs studied, two peptides,
vCPP 0769 and vCPP 2319, exhibited high antibacterial activity
against all bacterial strains tested. vCPP 0769 was particularly
active against S. aureus, MRSA and P. aeruginosa, with a MIC of
3.13 µM for these three bacteria, whereas for E. coli a MIC value
of 25 µM was obtained. vCPP 2319 displayed high antibacterial
activity against all bacterial strains tested, with a MIC of 1.56 µM
for S. aureus and MRSA, and 3.13 µM for E. coli and P.
aeruginosa.
Bactericidal Activity of Viral
Protein-Derived Peptides
To assess whether vCPP 0769 and vCPP 2319 are bactericidal
or bacteriostatic, their MBC was determined for all bacterial
strains tested. Peptides are considered bacteriostatic if their
TABLE 2 | Antibacterial activity of vCPPs.
Peptide MIC (µM)
S. aureus MRSA E. coli P. aeruginosa
vCPP 0275 25–50 50 12.5 100
vCPP 0417 >100 >100 25 100
vCPP 0667 50 100 12.5 25
vCPP 0769 3.13 3.13 25 3.13
vCPP 1779 100–>100 >100 25 25
vCPP 2319 1.56 1.56 3.13 3.13
MBC is more than fourfold their MIC, and bactericidal when
their MBC is equal or lower than four-fold their MIC (Levison
and Levison, 2009). The MBC values obtained are presented
in Table 3. vCPP 2319 exhibited bactericidal activity against
all bacterial strains tested. On the other hand, vCPP 0769
showed to be bactericidal only against E. coli and P. aeruginosa,
whereas for S. aureus and MRSA it only inhibited bacterial
growth. Additionally, the bactericidal activity of the peptide
vAMP 059 was also studied. This peptide was identified in our
previous screen for antimicrobial sequences from structural viral
proteins showing high antibacterial activity against S. aureus
and P. aeruginosa, with MIC values of 0.78 and 6.25 µM,
respectively (Freire et al., 2015a). MBC values showed the peptide
is bactericidal against both S. aureus and P. aeruginosa strains
tested.
Bactericidal Kinetics of Viral
Protein-Derived Peptides
The above-mentioned results show that vAMP 059 and vCPP
2319 are the most active peptides with a broad bactericidal
activity against the Gram-positive and Gram-negative bacterial
strains tested. Bacterial killing kinetics of S. aureus and
P. aeruginosa by vAMP 059 and vCPP 2319 were determined
at the MBC (Figure 1). In the presence of both peptides, a
significant reduction in the number of viable bacteria occurred
within minutes, although a faster bacterial killing was observed
for S. aureus (Figure 1A) when compared to P. aeruginosa
(Figure 1B). Both vAMP 059 and vCPP 2319 exhibited a fast
bactericidal activity against S. aureus with a reduction in bacterial
viability of 99.9 and 90.9%, respectively, after 30 min of peptide
activity. Both peptides exhibited a slower bactericidal activity
against P. aeruginosa. In this case, cell viability decreased more
gradually over time with a 99.7 and 97% reduction of bacterial
viability occurring after 180 min of exposure to vAMP 059 and
vCPP 2319, respectively.
Viral Protein-Derived Peptides Induce
Permeabilization of P. aeruginosa Cells
A fast bacterial killing kinetics is frequently observed for AMPs
and is related to their membrane-disrupting mode of action.
To investigate if peptides vAMP 059 and vCPP 2319 affect
bacterial membrane integrity, P. aeruginosa permeability to the
SYTOX Green dye was studied after treatment with increasing
peptide concentrations, with an increase in the dye fluorescence
intensity directly reflecting membrane permeabilization (Roth
et al., 1997). Results (Figure 2) showed an increase in membrane
TABLE 3 | Bactericidal activity of vCPP 0769, vCPP 2319, and vAMP 059.
Peptide MBC (µM)
S. aureus MRSA E. coli P. aeruginosa
vCPP 0769 >100 >100 50 6.25
vCPP 2319 3.13 3.13 3.13 3.13
vAMP 059 1.56 – – 6.25
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FIGURE 1 | Killing kinetics of S. aureus (A) and P. aeruginosa (B). Bacterial cells were exposed to the peptides vAMP 059 ( ) and vCPP 2319 (◦) at their MBC.
Viable bacteria (in CFU/mL) are reported as percentage of the control without peptide. Data correspond to mean ± SD of three independent experiments.
FIGURE 2 | Bacterial cells viability and membrane permeabilization after treatment with vAMP 059 (A) or vCPP 2319 (B). P. aeruginosa cells were
incubated with a range of concentrations of vAMP 059 or vCPP 2319 for 1 h at 37◦C. Viable bacteria (in CFU/mL) ( , ) and permeabilized bacteria (#, ) are
reported as a percentage of the control. Data correspond to mean ± SD of three independent experiments.
permeabilization with increasing peptide concentrations.
However, it was also noticed that at high concentrations of
both peptides there was a slight reduction in permeabilization.
Such result may be due to SYTOX Green displacement
from nucleic acids by the peptides, which would cause a
reduction in its fluorescence emission intensity and consequently
an apparent reduction in the percentage of permeabilized
bacteria.
Simultaneously with the SYTOX Green uptake assay, a
viability assay was performed for both peptides under the
same conditions. Results demonstrated a correlation between
P. aeruginosa permeability and viability in the presence of vAMP
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059 (Figure 2A) and vCPP 2319 (Figure 2B). These results show
that both peptides kill bacteria through membrane-disruption
mechanisms.
Bioimaging of the Viral Protein-Derived
Peptides Effect on P. aeruginosa Cells
Atomic force microscopy imaging was used to visualize the
morphological changes in P. aeruginosa after treatment with
vAMP 059 and vCPP 2319. The images obtained in air for
untreated P. aeruginosa cells (Figure 3A) showed, in all cases,
the characteristic rod shaped structure as well as a corrugated
surface with no visible pores or ruptures. Treatment of bacteria
with increasing concentrations of both peptides revealed a clear
effect on cell envelope integrity when compared with untreated
bacteria, although the cells maintained their global rod-like
form. After treatment with vAMP 059, a pronounced collapse in
P. aeruginosa cell envelope occurred at all concentrations tested
(Figures 3B–D). For vCPP 2319 a similar result was observed, but
a more gradual effect with increasing concentrations of peptide
was observed (Figures 3E–G). At 1.56 µM, a concentration
below MBC, only minor alterations on bacterial topography were
observed.
DISCUSSION
The therapeutic options for treatment of bacterial infections
are drastically decreasing due to a fast increase in drug
resistance. Driven by the need to discover new and effective
antimicrobial agents, this work has focused on a group of
promising alternatives, the AMPs.
In a previous study performed in our lab, we became
aware that, among AMPs and CPPs derived from natural
sources and listed on existing databases, only a few of them
were related to viral proteins. Using bioinformatic tools, a
set of peptide sequences with potential antimicrobial and
cell-penetrating properties was identified, suggesting that viruses
are an underexplored source for AMPs and CPPs (Freire et al.,
2015a). One viral protein-derived AMP (vAMP 059) and ten
viral protein-derived CPPs (vCPPs) were identified. In this study,
from the six more active vCPPs, we were able to identify
two peptides, vCPP 0769 and vCPP 2319, with concurrent,
strong antibacterial activity. vCPP 2319 demonstrated to be
active at low micromolar range concentrations, being bactericidal
against all the bacterial strains tested. vCPP 0769 revealed
high antibacterial activity against the S. aureus, MRSA and
P. aeruginosa strains, and a moderate activity against E. coli,
but only displayed bactericidal activity against the Gram-
negative bacterial strains tested. Therefore, both peptides reveal
a dual cell-penetrating and antibacterial activity, a peculiar
cross functionality that has been reported for few other
peptides (Takeshima et al., 2003; Nekhotiaeva et al., 2004;
Bobone et al., 2011). It has been proposed that peptides
with dual antimicrobial and cell-penetrating properties might
constitute potential candidates to target intracellular pathogenic
bacteria (Bahnsen et al., 2013; Torcato et al., 2013) that
escape host defenses (Ernst et al., 1999) and are extremely
difficult to treat with conventional antibiotics (Clement et al.,
2005).
In the present study, the results also show that the
previously identified viral protein-derived peptide vAMP 059,
with demonstrated activity against S. aureus and P. aeruginosa
(Freire et al., 2015a), revealed a bactericidal mode of action
against these bacterial strains. It is interesting to notice that
this peptide, as well as both vCPP 0769 and vCPP 2319, are
derived from viral capsid proteins (Freire et al., 2015a). Despite
the fact that only few viral-derived AMPs are known, there are
other examples of peptides with antimicrobial properties derived
from viral capsid proteins. HBc ARD, is a peptide derived from
the capsid protein of the human hepatitis B virus (Chen et al.,
2013), and pepR, derived from the putative RNA-binding domain
of the dengue virus capsid protein (Alves et al., 2010). Viral
capsid proteins are known as multifunctional proteins and some
of them can also be described as super charged proteins, a
class of proteins with high net charge to molecular mass ratio
and are known to have cell-membrane translocating properties
(Freire et al., 2015b). In fact, there are several examples of
cell-penetrating domains found in capsid proteins. With Dengue
virus capsid protein as an example, we showed that one of these
domains, the aforementioned pepR, also displays antibacterial
activity. This potential antibacterial activity of viral proteins may
have conferred viruses an evolutionary advantage over bacteria
(Freire et al., 2015b). Additionally, the presence of domains with
both antibacterial and cell-penetrating properties in viral capsid
proteins demonstrates the potential use of viral proteins in drug
discovery.
To get insights on the mode of action of the viral
protein-derived peptides, the most active peptides vAMP 059
and vCPP 2319 were studied. Both peptides revealed a fast
killing kinetics against S. aureus and P. aeruginosa. Since it
is known that antimicrobial agents that kill within minutes of
bacterial exposure, at concentrations similar to their MICs, act by
disrupting bacterial membranes (Zasloff, 2002; Melo et al., 2009),
we can suggest that both viral protein-derived peptides induce
bacterial death through membrane disruption. This behavior is
common amongst AMPs; for instance, the antimicrobial peptide
melittin, derived from bee venom, exhibits an extremely rapid
membrane-disrupting action, killing bacteria within minutes
(Kaplan et al., 2011). Additionally, when comparing vAMP 059
and vCPP 2319 killing kinetics on both bacterial strains tested
here, faster rates were observed against S. aureus than against
P. aeruginosa. This behavior can be related to the differential
peptide affinity for the molecular structures on Gram-negative or
Gram-positive bacteria envelope surfaces. Gram-positive bacteria
envelope consists on a single lipid membrane followed by a
thick peptidoglycan layer enriched in negatively charged teichoic
acids (Xia et al., 2010). In contrast, Gram-negative bacteria
possesses an inner cytoplasmic membrane surrounded by a thin
peptidoglycan layer and an outer membrane containing negative
lipopolysaccharides (LPS) (Beveridge, 1999). For instance,
the peptide rBPI21 exerts its antimicrobial activity through
interactions with LPS of the outer membrane of Gram-negative
bacteria, followed by fusion of the bacterial outer and inner
membranes (Domingues et al., 2009). In turn, the antimicrobial
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FIGURE 3 | Effect of vAMP 059 and vCPP 2319 on P. aeruginosa cells imaged by AFM. (A) AFM height image (left image) and three-dimensional projection
(right image) of P. aeruginosa cells incubated for 1 h in the absence of peptide (control). (B–G) AFM height images and three-dimensional projections of P. aeruginosa
cells incubated for 1 h with increasing concentrations of vAMP 059 (B–D) and vCPP 2319 (E–G). Total scanning area for each image was 4 µm × 4 µm.
peptide omiganan has high affinity for the peptidoglycan layer in
Gram-positive bacteria (Melo and Castanho, 2007). vAMP 059
and vCPP 2319 may have faster interaction with peptidoglycan
when compared to LPS, resulting on a faster killing kinetics
towards S. aureus rather than P. aeruginosa. The hypothesis
that vAMP 059 and vCPP 2319 cause bacterial cell membrane
disruption was confirmed in Gram-negative P. aeruginosa cells.
Both peptides induce permeabilization of the outer and inner
membranes, in a concentration-dependent manner, as shown
using the non-permeable SYTOX Green dye, which was able
to bind to the nucleic acids of bacterial cells treated with
peptide. A mechanism involving membrane disruption was
further confirmed by AFM imaging. Treatment of P. aeruginosa
cells with vAMP 059 induced a pronounced collapse at the septal
region of the cell envelope at all concentrations tested. Negatively
charged cardiolipin domains are located at the apical and septal
regions of E. coli cells (Mileykovskaya and Dowhan, 2000).
Assuming a similar cardiolipin-distribution for P. aeruginosa,
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the observed collapse in the mid-region could be explained by
accumulation of the peptides in these regions due to electrostatic
attractions between the positively charged peptides and these
negatively charged domains. Treatment of P. aeruginosa with
vCPP 2319 at concentrations below the MBC did not cause
substantial alterations on cell membrane morphology. However,
treatment with MBC, or higher, caused a marked collapse of the
membrane structure. Overall, AFM imaging suggested that both
peptides cause significant structural alterations on bacterial cell
surface, which is in agreement with the proposed hypothesis that
vAMP 059 and vCPP 2319 act at the membrane-level.
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